Shanghai Henlius Biotech's (HKG:2696) biologics license application for HLX11 has been accepted by the US Food and Drug Administration for two proposed indications, a Sunday Hong Kong bourse filing said.
The application is accepted for the use of the drug in two different combinations, as well as a standalone drug, to treat various forms of breast cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.